Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus
NCT03312335
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG:
Low-dose Aldesleukin (Proleukin®)
Sponsor
Onur Boyman, MD